Literature DB >> 15626719

Proximal tubular toxicity of ochratoxin A is amplified by simultaneous inhibition of the extracellular signal-regulated kinases 1/2.

C Sauvant1, H Holzinger, M Gekle.   

Abstract

Ochratoxin A (OTA) is a mycotoxin involved in the development of chronic nephropathies and a known carcinogen. As we have shown previously, OTA activates mitogen-activated protein kinases [extracellular signal-regulated kinase 1 and 2 (ERK1/2), c-jun amino-terminal kinase (JNK), and extracellular-regulated protein kinase 38 (p38)] in proximal tubular cells (opossum kidney and normal rat kidney epithelial). ERK1/2, JNK, or p38 are thought to mediate opposite action on apoptosis, fibrosis, and inflammation. As we have already shown, OTA activates the latter processes. Here, we investigated the effect of OTA in the absence or presence of the ERK1/2 inhibitor U0126 [1,4-diamino-2,3-dicyano-1,4bis(2-aminophenylthio)-butadiene] to test whether OTA then will exert increased toxicity. In the presence of ERK1/2 inhibition, OTA decreased cell number and protein to a significantly larger extent compared with OTA alone. The same was true for epithelial tightness, apoptosis (caspase-3 activity), and necrosis (lactate dehydrogenase release). Furthermore, simultaneous inhibition of ERK1/2 amplified the effect of OTA on markers of inflammation (nuclear factor of the kappa-enhancer in B cells activity), fibrosis (collagen secretion), and epithelial mesenchymal transition (alpha smooth muscle actin). OTA induces phenomena typical for chronic interstitial nephropathy and activates ERK1/2, JNK, and p38 in proximal tubular cells. Inhibition of ERK1/2 aggravates the effects of OTA or even induces toxicity at normally nontoxic concentrations. This is highly likely due to activation of JNK and p38. Our data indicate a new mechanistic explanation for the toxic actions induced by OTA, and they are notable with respect to a possible coexposition of the kidney to OTA and naturally occurring ERK1/2 inhibitors. Finally, our data give rise to an attractive hypothesis on the coincidence of increased OTA exposition and urinary tract tumors in humans.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15626719     DOI: 10.1124/jpet.104.079475

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  5 in total

1.  Ochratoxin a inhibits mouse embryonic development by activating a mitochondrion-dependent apoptotic signaling pathway.

Authors:  Yan-Der Hsuuw; Wen-Hsiung Chan; Jau-Song Yu
Journal:  Int J Mol Sci       Date:  2013-01-07       Impact factor: 5.923

2.  Differential cell sensitivity between OTA and LPS upon releasing TNF-α.

Authors:  Lauy Al-Anati; Ebtisam Essid; Ulla Stenius; Knut Beuerlein; Klaus Schuh; Ernst Petzinger
Journal:  Toxins (Basel)       Date:  2010-06-01       Impact factor: 4.546

3.  Evidence for a role of oxidative stress in the carcinogenicity of ochratoxin a.

Authors:  M Marin-Kuan; V Ehrlich; T Delatour; C Cavin; B Schilter
Journal:  J Toxicol       Date:  2011-06-22

4.  Assessment of Toxic Effects of Ochratoxin A in Human Embryonic Stem Cells.

Authors:  Slaven Erceg; Eva María Mateo; Iván Zipancic; Francisco Javier Rodríguez Jiménez; María Amparo Pérez Aragó; Misericordia Jiménez; José Miguel Soria; Mª Ángeles Garcia-Esparza
Journal:  Toxins (Basel)       Date:  2019-04-10       Impact factor: 4.546

5.  Kidney Injury Molecule-1 Is Upregulated in Renal Lipotoxicity and Mediates Palmitate-Induced Tubular Cell Injury and Inflammatory Response.

Authors:  Xueying Zhao; Xiaoming Chen; Yuanyuan Zhang; Jasmine George; Alyssa Cobbs; Guoshen Wang; Lingyun Li; Nerimiah Emmett
Journal:  Int J Mol Sci       Date:  2019-07-11       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.